VivoSeq
Other

Vaginal Delivery

0

Pipeline Programs

2

Active Trials

1

Companies Involved

Vaginal Delivery is an early-stage landscape with 0 programs across 1 company. The most active players are Ferring.

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

27

clinical trials

Completed17 · 63%
Unknown status5 · 19%
Withdrawn2 · 7%
Recruiting1 · 4%
Terminated1 · 4%
Not yet recruiting1 · 4%

Trial Activity

27 trials

Failure of Vaginal Delivery After Induction
Completed··Phase 3·NCT02758340·335 enrolled
Thermosensitive Gels for the Vaginal Delivery of Sildenafil Citrate
Completed··Phase 2/3·NCT02766725·90 enrolled
Prophylactic Tranexamic Acid Use After Vaginal Delivery
Completed··N/A·NCT05429580·480 enrolled
Epidural Morphine Following Vaginal Delivery
Completed·MMount Sinai Hospital, Canada·Phase 4·NCT00803114·228 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)